JPRN-UMIN000009568
Completed
未知
A Phase II Study of Eribulin Evaluating Efficacy and Safety as first or secondary line chemotherapy for advanced or metastatic breast cancer without HER2 overexpressing - OMC-BC03
General and Gastroenterological Surgery, Osaka Medical College0 sites35 target enrollmentDecember 21, 2012
ConditionsAdvanced or metastatic breast cancer
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Advanced or metastatic breast cancer
- Sponsor
- General and Gastroenterological Surgery, Osaka Medical College
- Enrollment
- 35
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\. serious complication or past history: with symptomatic heart failure, ischemic heart disease within 6 months, liver cirrhosis, psychological disorder treated by antipsychotic drug, uncontrolable diabetes, etc 2\. active infection 3\. The anamnesis of the hypersensitivity to Eribulin 4\. peripheral neuropathy greater than Grade 3 5\. male breast cancer 6\. under pregnancy or breast\-feeding, and possibility (will) of pregnancy. 7\. with doctors decision for exclusion
Outcomes
Primary Outcomes
Not specified
Similar Trials
Unknown
Phase 2
A study to evaluate the efficacy of Eribulin retreatment in HER2 negative Metastatic Breast Cancer patients - Phase II studyHER2-negative metastatic breast cancerJPRN-UMIN000027165Toho university30
Active, not recruiting
Phase 1
A Phase II study of a Combination of Eribulin and capecitabiNe in second line Treatment after the failure of gemcitabine/abraxane first line in advanced pancreatic canceradvanced pancreatic cancerMedDRA version: 21.0Level: LLTClassification code 10033599Term: Pancreatic adenocarcinoma metastaticSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2017-003621-15-ITAZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA25
Recruiting
Phase 2
Phase II study of the combination of Eribulin and Trastuzumab Evaluating Efficacy and Safety in Patients with advanced/recurrent HER2-positive breast cancer.Advanced/recurrent HER2-positive breast cancerJPRN-UMIN000011020Sairtama Breast Cancer Clinical Study Group (SBCCSG)na35
Completed
Phase 2
Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who presented well-defined taxane resistanceBreast CancerJPRN-UMIN000006965Saitama Breast Cancer Clinical Study Group (SBCCSG)52
Completed
Phase 2
A phase II study of eribulin in combination with trastuzumab and pertuzumab as First-Line therapy for metastatic HER2-positive breast cancerFirst-Line therapy for metastatic HER2-positive breast cancer.JPRN-UMIN000021585Sairtama Breast Cancer Clinical Study Group (SBCCSG)16